Q3 EPS Estimates for MiNK Therapeutics Lowered by B. Riley

Key Points

• B. Riley has lowered its Q3 2025 earnings per share estimate for MiNK Therapeutics from ($0.71) to ($0.91), while maintaining a "Strong-Buy" rating on the stock.
• MiNK Therapeutics recently faced mixed reviews from analysts, including a downgrade from Zacks Research to a "strong sell" and an upgrade from HC Wainwright to a "buy" with a price target of $35.00.
• The company's stock has shown volatility, with a 12-month price range of $4.56 to $76.00 and a recent opening price of $14.95.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Investment analysts at B. Riley decreased their Q3 2025 EPS estimates for MiNK Therapeutics in a report issued on Wednesday, August 20th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.91) per share for the quarter, down from their prior forecast of ($0.71). B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($2.75) per share. B. Riley also issued estimates for MiNK Therapeutics' Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($3.58) EPS, FY2026 earnings at ($4.17) EPS, FY2027 earnings at ($4.63) EPS, FY2028 earnings at $5.00 EPS and FY2029 earnings at ($5.43) EPS.

Other equities research analysts also recently issued reports about the stock. Zacks Research downgraded shares of MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, August 18th. HC Wainwright upgraded shares of MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price target on the stock in a research note on Friday, August 15th. William Blair downgraded shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Friday, July 11th. Finally, Wall Street Zen downgraded shares of MiNK Therapeutics to a "strong sell" rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $37.50.

MiNK Therapeutics Trading Down 2.2%

MiNK Therapeutics stock traded down $0.33 during trading hours on Friday, reaching $14.57. 17,341 shares of the stock were exchanged, compared to its average volume of 402,207. The stock has a 50 day moving average of $14.65 and a two-hundred day moving average of $10.41. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $76.00. The company has a market cap of $65.86 million, a P/E ratio of -5.06 and a beta of 0.33.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.51).

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.